Published on 9 Nov 2023 on GuruFocus.com via Yahoo Finance
X4 Pharmaceuticals Inc (XFOR) Reports Q3 2023 Financial Results and Corporate Progress
X4 Pharmaceuticals Inc (NASDAQ:XFOR) announced the FDA acceptance of its New Drug Application for mavorixafor with a PDUFA target action date of April 30, 2024.The company reported a significant reduction in net loss to $2.3 million for Q3 2023 compared to $21.6 million in Q3 2022.XFOR's cash reserves are robust at $142.7 million, believed to be sufficient into 2025, excluding potential additional funding sources.Research and Development expenses increased to $19.1 million, reflecting ongoing investment in clinical trials.
Warning! GuruFocus has detected 1 Warning Sign with XFOR.